DGX · Quest Diagnostics Inc · Investor Relations

(NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026. About Quest Diagnostics Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com View original content to download multimedia:

Women who test positive for bacterial vaginosis (BV) were over three times more likely to also test positive for one or more non-viral sexually transmitted infections (STIs) than women who test negative for BV, according to a new Health Trends® study from Quest Diagnostics (NYSE: DGX) and Hologic, Inc. In the largest national study of its kind, scientists at Quest and Hologic analyzed deidentified aggregated laboratory data from over 1.5 million women across the United States who received molecular testing from Quest between 2022 and 2024. Over one-third of women tested (38.7%) were positive for BV. Of these, 12% were co-infected with at least one STI. The findings were published in O&G Open , a peer-reviewed companion journal to Obstetrics & Gynecology , the official publication of the American College of Obstetricians and Gynecologists (ACOG). "BV is one of the most common health problems in women, and yet research in this area of women's healthcare is sadly lacking. Our new